Targeting CD33 in Chemoresistant AML Patient-Derived Xenografts by CAR-CIK Cells Modified with an Improved SB Transposon System

The successful implementation of chimeric antigen receptor (CAR)-T cell therapy in the clinical context of B cell malignancies has paved the way for further development in the more critical setting of acute myeloid leukemia (AML). Among the potentially targetable AML antigens, CD33 is insofar one of...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Mol Ther
Hlavní autoři: Rotiroti, Maria Caterina, Buracchi, Chiara, Arcangeli, Silvia, Galimberti, Stefania, Valsecchi, Maria Grazia, Perriello, Vincenzo Maria, Rasko, Tamas, Alberti, Gaia, Magnani, Chiara Francesca, Cappuzzello, Claudia, Lundberg, Felix, Pande, Amit, Dastoli, Giuseppe, Introna, Martino, Serafini, Marta, Biagi, Ettore, Izsvák, Zsuzsanna, Biondi, Andrea, Tettamanti, Sarah
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Gene & Cell Therapy 2020
Témata:
Original Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7474266/
https://ncbi.nlm.nih.gov/pubmed/32526203
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ymthe.2020.05.021
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky